Ashley Capoot

Monday - Friday, 6:00 - 7:00 PM ET CNBC's Jim Cramer on Thursday said it's no secret that the market rally has been driven by a handful of tech stocks, and it's not likely to change anytime soon.

The Supreme Court on Monday kicked issues around social media content moderation back to lower courts for further review.

Novo Nordisk, Eli Lilly and Pfizer are developing weight loss pills. Meanwhile, digital health funding shows 'measured momentum' this year, a report said.

Health-care workers at the VA are piloting technology and simulating procedures in a $43 million Florida-based facility called SimVET.

New study suggests that Novo Nordisk's Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group's cyberattack woes aren't over yet.

The neurotech startup Synchron is building a brain implant to try and help patients with paralysis control their phones, computers and other devices with their minds.

Republican representatives on Monday called on CrowdStrike CEO George Kurtz to testify after a defective software update caused disruptions across the globe.

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!

Shares of Dexcom tumbled more than 36% in after-hours trading Thursday after the diabetes management company released second-quarter results that missed analysts' expectations for revenue and offered weak guidance.

Dexcom, which had its stock market debut in 2005, is headed for its worst day ever after lowering its full-year guidance.